Plus   Neg

Retrophin: Phase 3 FORT Study Fails To Meet Endpoints - Quick Facts

Retrophin, Inc. (RTRX), a biopharmaceutical company, said the Phase 3 Study evaluating fosmetpantotenate compared to placebo in patients with pantothenate kinase-associated neurodegeneration failed to meet primary endpoint, as well as secondary endpoint. Fosmetpantotenate was generally safe and well-tolerated in the study.

Retrophin said the company will discuss with study investigators to decide the next steps for the FORT Study, including the ongoing open-label extension of the study.

Retrophin said it remains focused on advancing two pivotal Phase 3 programs evaluating sparsentan.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The media mogul and Billionaire Sumner Redstone passed away on Tuesday at the age of 97, his family's holding company National Amusements said in a statement on Wednesday. He was Chairman Emeritus of ViacomCBS and chief executive officer of National Amusements. Customers in the U.S. are preferring digital or touchless payment methods due to concerns arising from the COVID-19 pandemic, a survey said. According to the survey by Rapyd Financial Network, the coronavirus pandemic has raised health and safety concerns around using cash and coins, and is accelerating the pre-existing trend toward digital transactions. American Airlines has extended its offer to waive change fees for customers who purchase tickets for travel, until December 31, 2020 in response to lower travel demand due to the coronavirus pandemic. This means that the travelers need not pay penalties for changing the origin and destination cities.
Follow RTT